H.C. Wainwright raised its price target on Inventiva SA (NASDAQ:IVA) to $24.00 from $20.00, maintaining a Buy rating, following the company's Analyst Day which highlighted lanifibranor's unique position as the only oral, once-daily pan PPAR agonist in late-stage MASH development. The drug demonstrated superior efficacy in achieving MASH resolution and fibrosis improvement in trials, leading to revised success assumptions and positive coverage from multiple analysts. Despite the company not being expected to achieve profitability this year, it maintains strong liquidity, and its stock has delivered a 225% return over the past year, underscoring significant market interest in its lead therapeutic candidate.
Bitcoin price today: hovers above $123,000, but stays below record highs Investing.com - H.C. Wainwright raised its price target on Inventiva SA (NASDAQ:IVA) to $24.00 from $20.00 on Thursday, while maintaining a Buy rating on the stock. According to InvestingPro data, analyst targets for IVA range from $3 to $26, with the stock showing remarkable strength through a 225% return over the past year. The firm’s updated outlook follows Inventiva’s Analyst Day, which highlighted lanifibranor’s unique position as the only oral, once-daily pan PPAR agonist in late-stage development for MASH (metabolic dysfunction-associated steatohepatitis). While the company maintains a strong liquidity position with a current ratio of 2.96, InvestingPro analysis indicates the company is not expected to be profitable this year. H.C. Wainwright noted that lanifibranor remains the only agent to achieve both MASH resolution and ≥1 stage fibrosis improvement in a 24-week trial, demonstrating nearly 42% fibrosis improvement compared to 24% with placebo. The NATIV3 trial has now completed enrollment with nearly 1,000 F2/F3 patients plus approximately 400 exploratory cirrhotics in a 72-week study with a 48-week extension, including about 14% of patients on stable GLP-1 therapy. H.C. Wainwright revised its penetration and probability of success assumptions for lanifibranor based on its understanding of the MASH landscape, the drug’s emerging profile, and key opinion leader perspectives on the future therapeutic landscape for MASH. In other recent news, Inventiva has seen a series of notable developments. The company has been the subject of multiple analyst reviews, with Stifel reiterating a Buy rating and a $17.00 price target, emphasizing the unique profile of Inventiva’s lead drug candidate, lanifibranor. H.C. Wainwright also assumed coverage with a Buy rating and a $20.00 price target, noting the FDA’s acceptance of a letter of intent for using liver stiffness measurement as a surrogate endpoint. Guggenheim raised its price target for Inventiva from $9.00 to $13.00, citing increased enthusiasm for the MASH market and the target patient population for lanifibranor. Piper Sandler initiated coverage with an Overweight rating and a $26.00 price target, highlighting the potential of lanifibranor for treating metabolic dysfunction-associated steatohepatitis. Additionally, Inventiva announced leadership changes with Jason Campagna appointed as President of Research and Development and Chief Medical Officer, and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance. Campagna takes over from company co-founder Pierre Broqua, who will now serve as a Scientific Advisor. These developments reflect Inventiva’s ongoing strategic efforts and analyst interest in its drug pipeline. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Should you be buying IVA right now? ProPicks AI evaluates IVA alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if IVA is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space? H.C. Wainwright raised its price target for Inventiva SA (NASDAQ:IVA) to $24.00 from $20.00, maintaining a Buy rating, following the company's Analyst Day. This adjustment reflects revised penetration and probability of success assumptions for lanifibranor, the company's lead MASH drug, which has contributed to IVA's 225% stock return over the past year. Lanifibranor is highlighted as the sole oral, once-daily pan PPAR agonist in late-stage MASH development, demonstrating superior efficacy in trials. It achieved 42% fibrosis improvement versus 24% for placebo, making it the only agent to achieve both MASH resolution and ≥1 stage fibrosis improvement in a 24-week trial. The NATIV3 trial has completed enrollment, notably including approximately 14% of patients on stable GLP-1 therapy. Multiple analysts, including Stifel, Guggenheim, and Piper Sandler, have issued positive ratings and price targets up to $26.00, driven by increasing enthusiasm for the MASH market and FDA acceptance of liver stiffness as a surrogate endpoint. Despite strong liquidity with a 2.96 current ratio, the company is not expected to be profitable this year. Recent leadership changes also signal strategic advancement in R&D and regulatory affairs.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment
